US2003170300A1PendingUtilityA1

Combination chemotherapy

Priority: Sep 25, 1998Filed: Oct 8, 2002Published: Sep 11, 2003
Est. expirySep 25, 2018(expired)· nominal 20-yr term from priority
A61P 35/00A61P 35/04A61P 43/00A61P 1/18A61P 13/08A61K 45/06A61K 31/7068A61K 33/24A61K 31/70A61K 31/197A61K 33/243
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Acetyldinaline in combination with gemcitabine, a pharmaceutically acceptable salt thereof, capecitabine, or cisplatin is synergistic for treating cancer.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A combination of antineoplastic agents comprising an antitumor amount of acetyldinaline and an antitumor amount of gemcitabine, a pharmaceutically acceptable salt thereof, capecitabine, or cisplatin.  
     
     
         2 . A combination of  claim 1  comprising acetyldinaline formulated as a capsule.  
     
     
         3 . A combination of  claim 2  comprising gemcitabine or a pharmaceutically acceptable salt thereof formulated as a sterile solution for intravenous infusion.  
     
     
         4 . A combination of  claim 3  comprising gemcitabine monohydrochloride.  
     
     
         5 . A combination of  claim 3  comprising gemcitabine monohydrobromide.  
     
     
         6 . A combination of  claim 2  comprising cisplatin.  
     
     
         7 . A combination of  claim 2  comprising capecitabine.  
     
     
         8 . A method of treating cancer comprising administering to an animal in need of treatment an antitumor amount of a combination of  claim 1 .  
     
     
         9 . A method of  claim 8  wherein the cancer treated is nonsmall cell lung cancer.  
     
     
         10 . A method of  claim 9  comprising administering acetyldinaline in combination with gemcitabine monohydrochloride.  
     
     
         11 . A method of  claim 9  comprising administering acetyldinaline in combination with cisplatin.  
     
     
         12 . A method of  claim 9  comprising administering acetyldinaline in combination with capecitabine.  
     
     
         13 . A method of  claim 8  wherein the cancer treated is prostate cancer.  
     
     
         14 . A method of  claim 13  comprising administering acetyldinaline in combination with gemcitabine monohydrochloride.  
     
     
         15 . A method of  claim 13  comprising administering acetyldinaline in combination with cisplatin.  
     
     
         16 . A method of  claim 13  comprising administering acetyldinaline in combination with capecitabine.  
     
     
         17 . A method of  claim 8  wherein the cancer treated is a locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas.  
     
     
         18 . A kit comprising acetyldinaline in one compartment and gemcitabine or a pharmaceutically acceptable salt thereof in a second compartment.  
     
     
         19 . A kit comprising acetyldinaline in one compartment and cisplatin in a second compartment.  
     
     
         20 . A kit comprising acetyldinaline in one compartment and capecitabine in a second compartment.

Join the waitlist — get patent alerts

Track US2003170300A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.